Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5, 10 or 20 mg Once Daily for up to 14 Days in Patients With Hypertension

The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.

1. Office seated peripheral systolic and diastolic blood pressure
2. Adverse events and vital signs
3. Plasma concentrations of SLx-2101

Inclusion Criteria:

• Male or females between 18 and 80 years, inclusive
• Moderate to severe hypertension
• Body weight within a body mass index range of 18 - 32 kg/m2

Exclusion Criteria:

• Subject is receiving more than four antihypertensive agents
• History of drug abuse
• Exposure to a new chemical entity within 3 months prior to the first day of dosing